Categories: Corporate and commercial, Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Deals & Cases
Medartis (SIX: MED), an orthopedic company based in Basel specializing in head and extremity surgery, has acquired the remaining 53% of Geneva-based KeriMedical SA and is now the sole owner of the company. The value of the remaining shares amounts to CHF 99 million, plus potential additional earn-out payments.
KeriMedical is a leading provider of implants for hand and wrist surgery. Its flagship product, TOUCH®, for the treatment of osteoarthritis in the thumb, recently received approval from the US FDA and continues to drive the company's growth.
The partnership between Medartis and KeriMedical began in 2020, with Medartis serving as the exclusive distributor for KeriMedical products in several European countries and Australia, gradually increasing its stake. Through full integration, Medartis is strengthening its position in the field of joint replacement and further expanding its network of surgeons. KeriMedical will continue to operate as a separate brand within the Medartis Group. The co-founders will remain on the KeriMedical management board after the acquisition and will continue to contribute their experience in the development of additional clinical solutions.
VISCHER provided Medartis with comprehensive advice on legal issues relating to the acquisition. The VISCHER team consists of Christian Wyss (Partner, Corporate/M&A), Luzius Zumstein (Managing Associate, Corporate/M&A), Pauline Pfirter (Managing Associate, Corporate/M&A) and Rahel Widmer (Associate, Corporate/M&A).
Read the press release here: https://medartis.com/de/about-us/news
Author: Christian Wyss
